Preliminary results of a randomized trial of rituximab (475 mg/m²weekly for 4 weeks) or Y-90 ibritumomab tiuxetan (Zevalen^®) for patients with relapsed low grade B cell lymphomas.

Overall and complete response rates were significantly superior in the group receiving the radiolabeled anti-CD20 antibody compared with patients receiving rituximab (see text). Data plotted from the study by Witzig et al.³⁶